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Introduction {#s1}
============

A high percentage of young children in Kenya have inherited blood disorders. Among the most common in this region are α^+^-thalassemia, sickle cell hemoglobin (HbS), glucose-6-phosphate dehydrogenase (G6PD) deficiency, and haptoglobin (*Hp*) 2-2. A high prevalence of all of these disorders have been shown previously in Kenya and elsewhere in sub-Saharan Africa, with heterozygous α^+^-thalassemia (−α/αα) and homozygous (−α/−α) α^+^-thalassemia estimated at 39% and 15%, respectively, in coastal Kilifi,[@R1] sickle cell trait (HbAS) prevalence estimated at 15--28%,[@R2],[@R3] G6PD deficiency estimated as high as 20%,[@R4] and *Hp* 2-2 estimated as high as 25%.[@R5],[@R6]

All four blood disorders are associated with adverse health outcomes with varying severity and potential effect on nutrition status. Individuals with α^+^-thalassemia are largely asymptomatic, but experience chronic mild anemia.[@R7] HbAS is generally regarded as a benign condition, whereas sickle cell anemia (HbSS) is associated with chronic ill health and reduced life expectancy.[@R8] Individuals with G6PD deficiency are more susceptible to hemolytic anemia triggered by certain drugs or foods.[@R4] Inheritance of the *Hp* 2-2 genotype is not a blood disorder per se, but because the protein is active in iron metabolism, it may have a role in anemia.[@R9],[@R10]

The relationships between these four blood disorders and risk for anemia and malaria are multifaceted and have the potential to confound the interpretation of nutrition indicator outcomes if not taken into consideration. On one hand they may modify the risk of anemia and chronic malnutrition through reduced risk of severe malaria;[@R11],[@R12],[@R13] on the other hand some inherited blood disorders (including α^+^-thalassemia and HbSS) can have a negative impact on hemoglobin concentration and subsequent growth.[@R11],[@R14] For example, studies have linked HbSS with growth retardation and an increase in macronutrient requirements,[@R15],[@R16] whereas the prevalence of stunting was reported to be lower among young HbAS children who experienced malaria episodes in Ghana than among HbAA children.[@R13] Despite the potential for direct and indirect effects of anemia and malaria infection on growth and nutrition indicators, the relationships between inherited blood disorders and the overall nutritional status of young children are not well known. The confounding effects of inherited blood disorders are rarely considered in studies of nutrition in areas where inherited blood disorders are widespread.

Considering the high prevalence of blood disorders in sub-Saharan Africa, information about the relationship between them and children\'s risk for anemia, iron deficiency, vitamin A deficiency (VAD), and poor growth (stunting, underweight, wasting) can be useful for interpreting the results of nutrition surveys and monitoring the results of nutrition interventions.

Our purpose in this study was to investigate the relationship between each of four inherited blood disorders (*Hp* 2-2, G6PD deficiency, HbAS/HbSS, and the α^+^-thalassemia genotypes \[−α/αα,−α/−α\]) and the prevalence of six conditions associated with poor nutrition (anemia, iron deficiency, VAD, stunting, wasting, and underweight) among preschool children in western Kenya.

Methods {#s2}
=======

Study setting and design. {#s2a}
-------------------------

We used data from a population-based, cross-sectional survey of children who participated in the Nyando Integrated Child Health and Education Project (NICHE), a cluster randomized trial that evaluated the effectiveness of the promotion and sale of health products, including micronutrient powders, in 60 study villages during 2007--2010. A complete description of NICHE, including the study sampling methodology and results, are provided elsewhere.[@R17]--[@R20]

In brief, the survey was conducted in rural Nyando Division in Nyanza Province, western Kenya, where the population is of the Luo ethno-linguistic group and where the main occupation is subsistence farming; previously collected data from the NICHE project indicated a high rate of morbidity from malaria and poor nutrition among residents of this area.[@R20] In 2007, researchers used the 1999 Nyando District census as a reference to select 30 intervention villages and 30 comparison villages for participation in the survey, with the probability of a village\'s selection proportional to its size. An updated household census was conducted before the August 2010 survey, and 19 compounds per village were randomly selected. All children 6--35 months of age from each compound were eligible for inclusion in the survey. Of 1,079 age-eligible children, we included 861 in our analyses of survey data ([Figure 1](#F1){ref-type="fig"}); however, because of inadequate blood samples from some children, we did not include all 861 in all analyses. Field staff used birth certificates or immunization records to verify the ages of all children in the survey.

![Selection of survey participants in Nyando Division, Kenya.](tropmed-90-955-g001){#F1}

Assessment of children\'s nutritional status, hemoglobin genotype, and socioeconomic status. {#s2b}
--------------------------------------------------------------------------------------------

Field workers administered a questionnaire to a parent or other primary caretaker of participating children to collect information on the children\'s age, sex, illness status, and use of micronutrient supplementation. The questionnaire was written in English, translated into the local Dholuo language, and back-translated into English to verify the accuracy of the original translation. Caretakers were asked to report whether children had experienced diarrhea, respiratory disease, or fever within the preceding 24 hours, and clinical malaria was diagnosed on the basis of a positive malaria blood smear in conjunction with a report of fever in the preceding 24 hours. The survey also collected data on multiple indicators of socioeconomic status (SES), including maternal education, household assets, and infrastructure.

Trained anthropometrists measured the recumbent length of children \< 24 months of age and the standing height of those ≥ 24 months of age to the nearest 0.1 cm using a wooden measuring board (Irwin Shorr Productions, Olney, MD) and measured children\'s weight to the nearest 0.1 kg using a digital scale (Seca Corp., Hanover, MD). We defined stunting, underweight, and wasting as, respectively, a height-for-age *z*-score (HAZ), a weight-for-age *z*-score (WAZ), and a weight-for-height *z*-score (WHZ) less than two standard deviations below the mean values for these scores based on international growth standard data.[@R21]

Capillary blood was used for all hematological analyses. After wiping the first drop of blood, field workers measured the hemoglobin (Hb) concentration in the second drop using a HemoCue B-Hemoglobin device (Ängelholm, Sweden), collected 400--500 μL of blood in heparinized microcontainers, and made Giemsa-stained thick blood films. Microcontainers of collected blood were stored in cold boxes during the day until centrifugation each evening.

Anemia was defined as an Hb concentration \< 11.0 g/dL;[@R22] because all study villages were at elevations below 1,000 m, we did not apply an altitude correction. Collected blood samples were analyzed at the Kenyan Medical Research Institute (KEMRI)/Centers for Disease Control and Prevention (CDC) laboratory in Kisian, Kenya to determine whether malaria parasitemia were present and, if so, in what quantity. Children with severe anemia (Hb levels \< 7.0 g/dL) or clinically diagnosed malaria were referred to the nearest hospital or clinic for follow-up. Ferritin, C-reactive protein (CRP), transferrin receptor (TfR), α-1-acid glycoprotein (AGP), and retinol binding protein (RBP) were analyzed using a sandwich enzyme-linked immunosorbent assay (ELISA) technique (VitA-Iron Laboratory, Germany).[@R23] Low ferritin was defined as a plasma ferritin concentration \< 12 μg/L,[@R24],[@R25] and iron deficiency was defined as low ferritin in the absence of inflammation (a CRP level ≤ 5 mg/L and an AGP level ≤ 1 g/L).[@R26] Although TfR data were collected, we did not include it in this analysis because of the potential effect of malaria, inflammation, and hemoglobinopathies on TfR levels.[@R27] We defined low RBP as \< 0.7 μmol/L[@R28] and VAD as low RBP with no inflammation.

β-globin genotyping for the *HbA* and *HbS* alleles and the 3.7-kilobase α-globin chain deletion (the most common African form of α^+^-thalassemia) and the Hp genotypes were determined by polymerase chain reaction (PCR) as described in detail previously.[@R10],[@R29]--[@R31] On the basis of results from recent phenotypic studies (Shivang Shah, unpublished data), we classified males as G6PD-deficient if they were hemizygous for the G6PD^A−^ allele and females as G6PD-deficient if they were either homozygous for the G6PD^A−^ allele or heterozygous for both the G6PD^A−^ and G6PD^A^ alleles.[@R29],[@R32] All genetic analyses were conducted at the KEMRI-Wellcome Trust laboratory in Kilifi, Kenya; details of all analyses are available elsewhere.[@R17],[@R30],[@R31]

Iron supplementation and Sprinkles (a micronutrient powder) use were also assessed in the survey. The Sprinkles formulation used in this area included 14 micronutrients, including 12.5 mg of iron as microencapsulated ferrous fumarate and 375 μg of vitamin A.[@R33] SES was categorized in quintiles to relative poverty using a principal components analysis (PCA) wealth index developed by the World Bank.[@R34]

Data synthesis. {#s2c}
---------------

In our analyses, we categorized children into two age groups: 6--23 months and 24--35 months to capture those within the critical nutrition period of \< 24 months compared with those 24 months and over.[@R35] The Hb, ferritin, and RBP levels were dichotomized using the cut-off points defined previously because the primary objective was to identify whether nutritional status at internationally accepted definitions varied by blood disorder. Because only 30 children were classified as wasted, we did not include wasting as a covariate in logistic regression.

Statistical analysis. {#s2d}
---------------------

We used the Rao-Scott χ^2^ test[@R36] to identify crude associations between the blood disorders (primary exposure) and other variables. We then used logistic regression analysis to assess the relationship between each blood disorder and any nutrition outcome (anemia, low ferritin, low RBP, stunting, wasting, and underweight) shown to be statistically significant (χ^2^ *P* \< 0.05). The HbAA children served as the reference for those with HbAS, normal (αα/αα) genotype or heterozygote (−α/αα) children for α^+^-thalassemia homozygote children (−α/−α); children with normal G6PD levels for those with G6PD deficiency, and children with the *Hp* 1-1/*Hp* 2-1 genotype served as the reference group in analyses for *Hp* 2-2. Because only 14 children carried the HbSS genotype, we did not include these children in the logistic regression analysis.

In multivariable models, acute and chronic inflammation were accounted for by controlling for both CRP and AGP in the adjusted model.[@R26] We also assessed for interaction and confounding of covariates identified in previous studies, including male sex, low SES (defined as the bottom three PCA quintiles), illness (diarrhea, respiratory illness, or fever) within the preceding 24 hours, child-feeding practices in the preceding 24 hours (breastfeeding, tea consumption, iron supplementation, use of Sprinkles, dirt/earth consumption \[a form of pica behavior\]), inflammation (elevated CRP and/or AGP), and malaria status. To account for co-inheritance of blood disorders and co-existing health conditions, we also included nutrition outcomes and blood disorders as covariates in initial models. Blood disorders were retained in final models regardless of *P* value.

We included covariates in our full logistic regression model if results of our bivariate analysis indicated there was a significant association with a blood disorder (*P* \< 0.05), if the interaction between the primary exposure and covariate was significant (*P* \< 0.05), or if they changed the odds ratio (OR) for the relationship between the primary exposure and the covariate by more than 10%. We conducted backward regression first for any interaction terms and then by removing variables that were not confounders or independent predictors of the outcome. At each step, we monitored the OR for the relationship between the primary exposure and the covariate to ensure that removal of a covariate did not result in confounding. However, we kept age, sex, and all other blood disorders in the model as potential confounding covariates regardless of the *P* value for their relationship with a blood disorder of interest. We used the same process for all significant associations between blood disorders and indicators of poor nutrition. We defined collinearity between covariates as condition indices (CI) \> 30 using a SAS colinearity macro[@R37] in the final models. Final models included all remaining significant two-way interactions, statistically significant independent variables, and confounding variables as defined above.

Data were analyzed using SAS version 9.3 (SAS Institute Inc., Cary, NC) taking into account the complex survey design of 60 primary sampling units (villages) by using PROC SURVEYFREQ and PROC SURVEYLOGISTIC. We considered results to be statistically significant if two-sided *P* values were \< 0.05.

Ethical considerations. {#s2e}
-----------------------

The Scientific Steering Committee and the Ethical Review Committee of KEMRI in Nairobi and the CDC Institutional Review Board approved all study protocols.

Results {#s3}
=======

We classified 29.8% of children surveyed as stunted, 12.1% as underweight, 3.5% as wasted, 19.1% as having low ferritin levels, and 30.9% as having low RBP levels ([Table 1](#T1){ref-type="table"}). We classified 59.4% as having one or more of the following genotypes or conditions: *Hp* 2-2, G6PD deficiency, α^+^-thalassemia, or HbAS/HbSS. In the overall population, 38.6% were α^+^-thalassemia heterozygotes, 9.6% α^+^-thalassemia homozygotes, 20.4% had *Hp* 2-2, 17.0% had HbAS, 1.6% had HbSS, and 6.8% had G6PD deficiency; the prevalence of these genotypes and conditions did not differ significantly by sex (data not shown).

Anemia prevalence did not differ significantly by Hp subtype, HbS genotype, or G6PD deficiency status ([Table 2](#T2){ref-type="table"}). However, the prevalence of anemia did differ significantly by α^+^-thalassemia strata (overall trend *P* = 0.003, not shown), with the prevalence being significantly higher among homozygotes compared with heterozygotes (*P* = 0.014) or the normal genotype (*P* = 0.001). Both heterozygotes and homozygotes were more likely to have anemia than were those with normal genotype (crude ORs = 1.53 and 2.31, respectively, not shown).

We found no significant bivariate association between low ferritin levels and any of the blood disorders investigated. The prevalence of low RBP was significantly lower among children with homozygous α^+^-thalassemia (*P* = 0.024) compared with those with normal genotype; however, the prevalence of low RBP did not differ significantly between α^+^-thalassemia heterozygous children and those with normal genotype (*P* = 0.600). There was no significant relationship between low RBP status and any of the other blood disorders. After we removed children with any inflammation (*N* = 517; 60.8% of the study population) from our analyses for VAD and iron deficiency, iron deficiency was not associated with any disorders and VAD was associated only with the heterozygous α^+^-thalassemia genotype (*P* = 0.034, not shown). Given the high percentage of children excluded because of inflammation, we did not conduct a logistic regression analysis of the relationship between VAD (RBP \< 0.7 μmol/L and no inflammation) and α^+^-thalassemia.

Inflammation was not significantly associated with any of the inherited blood disorders; elevated CRP varied from 21.4--37.2%, whereas elevated AGP varied from 53.6--64.3% among the disorders (not shown). None of the inherited blood disorders were associated with the prevalence of stunting, wasting, or underweight.

Relationship between homozygous α^+^-thalassemia (−α/−α) and low RBP. {#s3a}
---------------------------------------------------------------------

After adjusting for significant covariates, multivariate logistic regression results showed no significant relationship between homozygosity for α^+^-thalassemia and low RBP (aOR = 0.61, *P* = 0.065; 95% CI = 0.36--1.03) but did show low RBP to be associated with a greater prevalence of being underweight, having inflammation, and testing positive for malaria ([Table 3](#T3){ref-type="table"}). We retained age group in the regression model to control for any confounding as a result of survival bias, and we kept HbAS, *Hp* 2-2 and G6PD deficiency in the model as potential confounders because of co-inheritance of blood disorders. We found no evidence of significant colinearity among the independent variables.

Relationship between α^+^-thalassemia (−α/αα, −α/−α) and anemia. {#s3b}
----------------------------------------------------------------

After adjusting for significant covariates, α^+^-thalassemia was still positively associated with anemia (*P* = 0.004) ([Table 4](#T4){ref-type="table"}); children with α^+^-thalassemia were significantly more likely to have anemia than those without (aOR = 1.78; 95% CI = 1.20--2.62). Other variables in the adjusted model associated with anemia were young age (6--23 months), low SES, male sex, low ferritin concentration, inflammation, and a positive malaria smear. Of these, a positive malaria smear (aOR = 6.81, 95% CI = 4.26--10.89), a low ferritin concentration (aOR = 4.43, 95% CI = 2.67--7.32), and inflammation (aOR = 3.24, 95% CI = 2.04--5.14) had the strongest associations with anemia. We kept HbAS, *Hp* 2-2, and G6PD deficiency in the model as potential confounders and found no evidence of significant colinearity among the covariates.

Discussion {#s4}
==========

Despite a high prevalence of both malnutrition and inherited blood disorders in this population, we found no significant associations between the blood disorders and conditions indicative of poor nutrition, except for a positive association between α^+^-thalassemia and anemia, which has been found previously Kenya, Nigeria, and Cambodia population.[@R1],[@R14],[@R38] Thus, our results suggest that α^+^-thalassemia should be considered when evaluating anemia etiology and the impact of anemia interventions. However, there may be limited value of the other measured blood disorders (G6PD deficiency, *Hp* 2-2, and HbAS) in interpreting cross-sectional nutrition surveys.

Although anemia prevalence differed by α^+^-thalassemia genotype, the prevalence of low ferritin levels did not. Our finding is consistent with a previous study among children on the coast of Kenya.[@R39] It is well known that anemia prevalence in children with α^+^-thalassemia is associated with the disorder itself or another mechanism associated with the disorder, rather than with α^+^-thalassemia\'s relationship to iron metabolism.[@R7],[@R40]

The relationship between α^+^-thalassemia and anemia is especially important in locations such as western Kenya where malaria is endemic and the prevalence of α^+^-thalassemia (48.2% overall) is high. Awareness of the underlying prevalence of blood disorders in a population may help program officials better interpret the impact of interventions to prevent and treat anemia. Impact evaluations of anemia prevention or treatment programs may not be a true reflection of program success because anemia attributable to α^+^-thalassemia will not be corrected. Though systematic screening for α^+^-thalassemia may be unrealistic in regions with limited resources, partial population sampling or understanding of the distribution of α^+^-thalassemia are potential tools that could be considered during monitoring and evaluation of anemia control programs.

We found a relatively high prevalence of low RBP and VAD across all blood disorder subgroups.[@R41] We also found that low RBP status was associated with being underweight, having a positive malaria smear, and having elevated levels of inflammatory markers. Clinical trial results have shown that vitamin A supplementation can decrease the parasite load,[@R42] but it is unclear if vitamin A supplementation has any effect on malarial infection in an endemic area such as Nyando.[@R43]

Although our unadjusted results showed an inverse association between homozygous α^+^-thalassemia and low RBP, this relationship was no longer significant after we controlled for other variables. However, our fully adjusted results were close to statistical significance, and our nonsignificant finding may be a result of the low number of children in our study population who had homozygous α^+^-thalassemia. If homozygosity for α^+^-thalassemia and RBP levels is truly associated, studies of potential mechanisms behind this association and studies of the relationship between α^+^-thalassemia and VAD in a population with a lower prevalence of inflammation may be warranted.

Our finding that HbAS was not associated with stunting or anemia was inconsistent with previous findings.[@R44],[@R45] However, there is evidence that biological interactions among co-inherited hemoglobinopathies[@R46] may have limited our ability to detect any such reduction in prevalence associated with HbAS. Additionally, because of low sample sizes, we were unable to assess nutritional status with HbSS, which has been shown to be associated with stunting and micronutrient deficiencies.

Our findings also did not indicate a relationship between nutritional outcomes and either G6PD deficiency or Hp polymorphism, which was unexpected given that both blood disorders have previously been associated with malaria.[@R5],[@R47] Theoretically, people at increased malarial risk from *Hp* 2-2 and exposure to hemolytic events from G6PD deficiency would be at higher risk for chronic anemia, with expected consequences on growth indicators.

It is important to note that in low-resource environments where the prevalence of disease is high throughout the population, any additional disease attributable to inherited blood disorders may be difficult to detect. In addition, as a cross-sectional study, survival bias is a potential confounding factor in the relationship between disease prevalence and either HbSS or G6PD deficiency. In our study cohort, HbSS children were, on average, 8 months younger than those with other genotypes, suggesting that older HbSS children may not have survived. Severe symptoms of G6PD deficiency include neonatal complications such as jaundice, which may lead to death if not treated. As such, we were not able to assess the relationship between nutrition and blood disorders among children with severe forms of these diseases.

In communities with a higher SES distribution and lower rates of child morbidity and mortality attributable to poor sanitation and infectious diseases, child survival will likely be more common. As health outcomes improve in populations with a high prevalence of inherited blood disorders and more children reach adulthood, it will be even more important to understand how inherited blood disorders may be associated with poor nutrition.

Study strengths and limitations. {#s4a}
--------------------------------

A strength of this study was our analysis of data based on the measurement of multiple nutrition biomarkers and the genotyping of multiple blood disorders. However, because of the cross-sectional survey design, any associations between blood disorders and conditions related to malnutrition do not necessarily indicate a causal relationship. In addition, the use of OR in a cross-sectional study overstates the prevalence ratio because the outcomes studied in this analysis are common.

Other study limitations included potential information bias from self-reported household data, analysis of data from a relatively small area of Kenya (Nyando Division), which may not be representative of the country as a whole, and inability to assess to what magnitude blood disorders change hematologic nutrition indicators. In addition, the survey tool did not collect data on other potential confounding factors such as helminth or roundworm parasite infections, vitamin A supplementation, and recent treatment with antimalarial medication, which limited analyses.

Conclusion {#s5}
==========

Our findings showed that in western Kenya, an area with a high prevalence of childhood malnutrition, inherited blood disorders are not associated with most indicators of poor nutritional status. There may be limited value in assessing blood disorders for measuring certain nutritional outcomes, such as growth. The only significant association we found was between α^+^-thalassemia and anemia. Regional anemia prevalence estimates should take this association into consideration when interpreting anemia etiologies and when recommending nutritional interventions such as iron supplementation.
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###### 

Characteristics and health indicators of children aged 6--35 months in western Kenya, 2010[\*](#TFN1){ref-type="table-fn"}

  Total sample size = 861                                                 n/*N*     \%
  ----------------------------------------------------------------------- --------- ------
  Sex, female                                                             427/861   49.6
  Age, 6--23 months                                                       463/861   53.8
  Child slept under bed net previous night                                777/837   92.8
  Inherited blood disorders                                                         
   G6PD deficiency                                                        56/829    6.8
   Haptoglobin polymorphism, *Hp* 2-2                                     164/805   20.4
   α^+^-Thalassemia                                                                 
    Heterozygotes (αα/−α)                                                 319/826   38.6
    Homozygotes (−α/−α)                                                   79/826    9.6
   Sickle cell hemoglobin                                                           
    Trait (HbAS)                                                          146/857   17.0
    SCA (HbSS)                                                            14/857    1.6
  Nutrition status                                                                  
   Anemia (Hb \< 11 g/dL)                                                 617/861   71.7
   Plasma ferritin \< 12 μg/L[†](#TFN2){ref-type="table-fn"}              162/850   19.1
    Iron deficiency[‡](#TFN3){ref-type="table-fn"}                        124/333   37.2
   Retinol binding protein \< 0.7 μmol/L[†](#TFN2){ref-type="table-fn"}   263/850   30.9
    Vitamin A deficiency[‡](#TFN3){ref-type="table-fn"}                   52/333    15.6
   Inflammation                                                                     
    C-reactive protein \> 5.0 mg/L                                        292/850   34.4
    α~1~-acid glycoprotein \> 1.0 g/L                                     518/850   60.9
    Any inflammation (AGP \> 1.0 g/L or   CRP \> 5.0 mg/L)                528/861   61.3
   Anthropometry                                                                    
    Stunted (HAZ \< −2.0)                                                 255/856   29.8
    Underweight (WAZ \< −2.0)                                             104/859   12.1
    Wasted (WHZ \< −2.0)                                                  30/857    3.5
  Nutrition practices                                                               
   Sprinkles (in last 24 hr)                                              92/837    11.0
   Iron supplementation (in last 24 hr)                                   58/839    6.3
   Tea consumption (in last 24 hr)                                        692/832   83.2
   Breast-feeding (in last 24 hr)                                         417/838   49.8
   Self-reported pica (in last 24 hr)                                     382/800   47.8
  Illness                                                                           
   Clinical malaria                                                       124/857   14.5
   Diarrhea (in last 24 hr)                                               203/836   24.3
   Fever (in last 24 hr)                                                  349/829   42.1
   Respiratory (in last 24 hr)                                            319/839   38.0

G6PD = glucose-6-phosphate dehydrogenase; SCA = sickle cell anemia; Hb = hemoglobin; HAZ = height-for-age z-score; WAZ = weight-for age z-score; AGP = α1-acud glycoprotein; CRP = C-reactive protein.

Uncorrected for inflammation.

Excludes *N* = 517 children with elevated CRP and/or AGP.

###### 

Nutrition and anthropometry indicators of participant children by blood disorder in western Kenya, 2010[\*](#TFN4){ref-type="table-fn"}[†](#TFN5){ref-type="table-fn"}

                                             Anemia (Hb \< 11 g/dL) *N* = 861   Ferritin \< 12 μg/L[‡](#TFN6){ref-type="table-fn"} *N* = 850   RBP \< 0.7 μmol/L[‡](#TFN6){ref-type="table-fn"} *N* = 850   Stunted (HAZ \< −2), % *N* = 856   Underweight (WAZ \< −2), % *N* = 859   Wasted (WHZ \< −2), % *N* = 857
  ------------------------------------------ ---------------------------------- -------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------- -------------------------------------- ---------------------------------
  G6PD deficiency, *N* = 829                                                                                                                                                                                                                                                          
   Normal                                    551/773 (71.3)                     148/766 (19.3)                                                 238/766 (31.1)                                               228/769 (29.6)                     95/771 (12.3)                          29/770 (3.8)
   Deficient                                 40/56 (71.4)                       9/56 (16.1)                                                    14/56 (25.0)                                                 21/56 (37.5)                       8/56 (14.3)                            1/56 (1.8)
    *P* value (ref = normal)                 0.980                              0.546                                                          0.323                                                        0.148                              0.670                                  0.455
  Hp polymorphism, *N* = 858                                                                                                                                                                                                                                                          
   *Hp* 1-1 or *Hp* 2-1                      457/641 (71.3)                     118/633 (18.6)                                                 187/633 (29.5)                                               190/638 (29.8)                     76/640 (11.9)                          23/639 (3.6)
   *Hp* 2-2                                  122/164 (74.4)                     33/164 (20.1)                                                  59/164 (36.0)                                                49/163 (30.1)                      21/163 (12.9)                          6/163 (3.7)
    *P* value (ref = *Hp* 1-1 or *Hp* 2-1)   0.411                              0.686                                                          0.088                                                        0.940                              0.689                                  0.951
  α^+^-Thalassemia, *N* = 826                                                                                                                                                                                                                                                         
   Normal (αα/αα)                            286/428 (66.8)                     80/427 (18.7)                                                  134/427 (31.4)                                               131/426 (30.8)                     56/428 (13.1)                          17/427 (4.0)
   Heterozygotes (−α/αα)                     241/319 (75.6)                     60/313 (19.2)                                                  104/313 (33.2)                                               93/318 (29.2)                      34/319 (10.7)                          10/319 (3.1)
    *P* value (ref = αα/αα)                  0.014                              0.894                                                          0.600                                                        0.677                              0.340                                  0.595
   Homozygotes (−α/−α)                       65/79 (82.3)                       16/78 (20.5)                                                   16/78 (20.5)                                                 22/78 (28.2)                       12/77 (15.6)                           3/77 (3.9)
    *P* value (ref = αα/αα)                  0.001                              0.717                                                          0.024                                                        0.668                              0.550                                  0.968
  HbS, *N* = 857                                                                                                                                                                                                                                                                      
   Normal (HbAA)                             504/697 (72.3)                     127/691 (18.4)                                                 215/691 (31.1)                                               200/693 (28.9)                     81/695 (11.7)                          26/694 (3.7)
   Trait (HbAS)                              101/146 (69.2)                     34/144 (23.6)                                                  46/144 (31.9)                                                52/146 (35.6)                      22/146 (15.1)                          4/146 (2.7)
    *P* value (ref = HbAA)                   0.466                              0.154                                                          0.847                                                        0.086                              0.169                                  0.475
   SCA (HbSS)                                10/14 (71.4)                       1/14 (7.14)                                                    1/14 (7.1)                                                   3/14 (21.4)                        1/14 (7.14)                            0/14 (0)
    *P* value (ref = HbAA)                   0.945                              0.273                                                          0.056                                                        0.504                              0.584                                  --

Data presented are numerator/denominator (percentage).

Hb = Hemoglobin; RBP = retinol binding protein; HAZ = height-for-age z-score; WAZ = weight-for-age z score; WHZ = weight-for-height z-score; G6PD = glucose-6-phosphate dehydrogenase; *Hp* = haptoglobin; SCA, sickle cell anemia.

Uncorrected for inflammation.

###### 

Factors associated with low RBP among young children aged 6--35 months in western Kenya, 2010[\*](#TFN7){ref-type="table-fn"} (*N* = 756)

  Variable                                          Unadjusted OR                         Adjusted model      
  ------------------------------------------------- ------------------------------------- ------------------- ----------
  Primary exposure                                                                                            
   α^+^-Thalassemia: −α/−α (ref = αα/αα or −α/αα)   0.54[†](#TFN8){ref-type="table-fn"}   0.61 (0.36--1.03)   0.065
  Child demographics and characteristics                                                                      
   Age 6--23 months (ref = 24--35 months)           0.98                                  1.12 (0.79--1.70)   0.451
   Underweight (ref = WAZ ≥ −2)                     2.30[†](#TFN8){ref-type="table-fn"}   1.96 (1.15--3.34)   0.014
  Morbidity and infection                                                                                     
   Inflammation (ref = normal CRP and AGP)          4.97[†](#TFN8){ref-type="table-fn"}   3.33 (2.14--5.18)   \< 0.001
   Positive malaria smear (ref = no malaria)        3.90[†](#TFN8){ref-type="table-fn"}   2.72 (1.91--3.87)   \< 0.001
  Blood disorders                                                                                             
   G6PD deficiency (ref = normal)                   0.74                                  0.84 (0.41--1.69)   0.615
   HbAS (ref = HbAA)                                0.86                                  1.05 (0.66--1.69)   0.829
   *Hp* 2-2 (ref = *Hp* 1-1 and *Hp* 2-1)           1.34                                  1.41 (0.97--2.05)   0.074

RBP = retinol binding protein; WAZ = weight-for-age z score; Inflammation = CRP \> 5 mg/L and/or AGP \> 1 g/L; Normal AGP/CRP = CRP ≤ 5 mg/L, AGP ≤ 1 g/L; G6PD = glucose-6-phosphate-dehydrogenase; HbAS = sickle cell trait; *Hp*, haptoglobin.

Unadjusted odds ratio (OR) *P* \< 0.05.

###### 

Factors associated with anemia among young children aged 6--35 months in western Kenya, 2010[\*](#TFN9){ref-type="table-fn"} (*N* = 739)

  Variable                                         Unadjusted OR                          Adjusted model       
  ------------------------------------------------ -------------------------------------- -------------------- ----------
  Primary exposure                                                                                             
   α^+^-Thalassemia −α/αα or −α/−α (ref = αα/αα)   1.65[†](#TFN10){ref-type="table-fn"}   1.78 (1.20--2.62)    0.004
  Child demographics and characteristics                                                                       
   Age 6--23 months (ref = 24--35 months)          1.48[†](#TFN10){ref-type="table-fn"}   1.35 (0.91--2.01)    0.140
   Breastfeeding in the last 24 hours              1.54[†](#TFN10){ref-type="table-fn"}   1.38 (0.94--2.05)    0.103
   SES quintile 1--3 (ref = quintile 4--5)         1.44[†](#TFN10){ref-type="table-fn"}   1.52 (1.06--2.19)    0.024
   Male (ref = female)                             1.51[†](#TFN10){ref-type="table-fn"}   1.66 (1.06--2.59)    0.026
   Underweight (ref = WAZ ≥ −2)                    2.20[†](#TFN10){ref-type="table-fn"}   1.85 (1.02--3.34)    0.043
  Morbidity and infection                                                                                      
   Low iron (ref = ferritin ≥ 12 μg/L)             1.79[†](#TFN10){ref-type="table-fn"}   4.43 (2.67--7.32)    \< 0.001
   Inflammation (ref = normal CRP & AGP)           3.43[†](#TFN10){ref-type="table-fn"}   3.24 (2.04--5.14)    \< 0.001
   Positive malaria smear (ref = no malaria)       5.79[†](#TFN10){ref-type="table-fn"}   6.81 (4.26--10.89)   \< 0.001
  Blood disorders                                                                                              
   G6PD deficiency (ref = normal)                  1.01                                   1.01 (0.45--2.31)    0.906
   HbAS (ref = HbAA)                               0.47                                   0.69 (0.41--1.16)    0.165
   *Hp* 2-2 (ref = *Hp* 1-1 or *Hp* 2-1)           1.23                                   0.97 (0.63--1.50)    0.905

SES = socioeconomic status; WAZ = weight-for-age z score; Inflammation = CRP \> 5 mg/L and/or AGP \> 1 g/L; Normal AGP/CRP = CRP ≤ 5 mg/L, AGP ≤ 1 g/L; G6PD = glucose-6-phosphate-dehydrogenase; HbAS = sickle cell trait; *Hp*, haptoglobin.

Unadjusted odds ratio (OR) *P* \< 0.05.
